Shares of Arsanis Inc (NASDAQ:ASNS) reached a new 52-week low during trading on Tuesday . The stock traded as low as $1.65 and last traded at $1.67, with a volume of 411 shares changing hands. The stock had previously closed at $1.80.

Several analysts recently commented on ASNS shares. Zacks Investment Research upgraded shares of Arsanis from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Tuesday, July 10th. Cantor Fitzgerald restated a “buy” rating and set a $26.00 price target on shares of Arsanis in a research report on Thursday, June 28th. Cowen lowered shares of Arsanis from an “outperform” rating to a “market perform” rating in a research report on Monday, July 2nd. Piper Jaffray Companies dropped their price target on shares of Arsanis to $2.50 and set a “neutral” rating on the stock in a research report on Monday, August 13th. Finally, Citigroup lowered shares of Arsanis from a “buy” rating to a “neutral” rating in a research report on Monday, July 9th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Arsanis currently has a consensus rating of “Hold” and an average price target of $14.88.

The company has a debt-to-equity ratio of 0.20, a quick ratio of 5.54 and a current ratio of 5.54. The firm has a market cap of $25.34 million and a PE ratio of -0.11.

Arsanis (NASDAQ:ASNS) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.03). analysts predict that Arsanis Inc will post -3.12 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in Arsanis by 6.4% during the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock valued at $5,663,000 after purchasing an additional 14,819 shares in the last quarter. BlackRock Inc. lifted its holdings in Arsanis by 27.1% during the second quarter. BlackRock Inc. now owns 223,797 shares of the company’s stock valued at $812,000 after purchasing an additional 47,777 shares in the last quarter. Granahan Investment Management Inc. MA purchased a new position in Arsanis during the second quarter valued at $365,000. Northern Trust Corp purchased a new position in Arsanis during the first quarter valued at $735,000. Finally, Millennium Management LLC purchased a new position in Arsanis during the fourth quarter valued at $299,000. 68.70% of the stock is currently owned by institutional investors and hedge funds.

About Arsanis (NASDAQ:ASNS)

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Read More: Outstanding Shares

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.